Investigating a new way to target cancer therapy through p53 protein modification
Validating p53 Ser46 crotonylation as a potential target for possible anti-cancer therapy
This study is looking at how certain substances from gut bacteria, especially crotonic acid, might affect a protein called p53 that helps prevent cancer, specifically in colorectal cancer, to find new ways to improve treatment and show how what we eat and our gut health can impact cancer growth.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tulane University of Louisiana NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project ID | NIH-10671541 on NIH RePORTER |
What this research studies
This research explores how gut microbiota and their byproducts, specifically crotonic acid, may influence the p53 protein, which plays a crucial role in preventing cancer. The study focuses on understanding how crotonylation of p53 at serine 46 affects its levels and activity in colorectal cancer cells. By examining the relationship between gut health and cancer development, the research aims to uncover new therapeutic targets that could enhance cancer treatment. Patients may benefit from insights into how dietary factors and gut bacteria influence cancer progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with colorectal cancer, particularly those with wild type p53.
Not a fit: Patients with advanced colorectal cancer where p53 is already mutated may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to novel anti-cancer therapies that target the p53 protein, potentially improving treatment outcomes for colorectal cancer patients.
How similar studies have performed: While the specific approach of targeting p53 crotonylation is novel, previous research has shown that gut microbiota can influence cancer pathways, indicating potential for success.
Where this research is happening
New Orleans, United States
- Tulane University of Louisiana — New Orleans, United States (Active)
Researchers
- Principal investigator: Lu, Hua — Tulane University of Louisiana
- Study coordinator: Lu, Hua
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.